By CERBIOS-PHARMA SA
To get in touch with CERBIOS-PHARMA SA, simply fill out the form below.
Subscribe to Supplier
Cerbios-Pharma and PROVEO present payload and conjugation manufacturing services at ADC World London
Lugano, Switzerland: – Pharmaceutical ingredient specialist Cerbios-Pharma SA (Cerbios) is returning to the World ADC Europe Congress in London to showcase its advanced integrated antibody drug conjugate solutions.
Cerbios will exhibit as part of the multinational PROVEO Alliance (incuding AGC Biologics and Oncotec) from Booth 18 at the Hammersmith International Expo Centre in London. The Cerbios and PROVEO teams will promote the alliance’s integrated development and cGMP manufacturing services for ADCs conjugation, cytotoxic payloads, recombinant proteins (incl mAbs) and Fill Finish. The novel Cerbios manufacturing technology for ADCs will also be introduced.
Integrated ADC solutions
Business Development Manager Dr. Matteo Piazza and R&D Senior Manager Vitor Sousa will represent Cerbios-Pharma in London.
“This is a return to the ADC World congress following highly successful participations in the past worldwide events” noted Dr. Piazza.
“We will be promoting our integrated ADC manufacturing services that provide seamless one-stop-shop solutions for small and mid-size pharma manufacturers,” he said.
Cerbios will host a special invitation-only lunch on Day Two of the conference, featuring scientific presentations from Dr Pozzoli (CSO of Cerbios) and Dr Porzio (QC head of ADIENNE Pharma and Biotech).
“We will be an active presence during all the networking events organized in the congress, which is a superb opportunity to strengthen our links with pharma companies, start-ups and innovators active in the ADC field,” said Dr. Sousa.
“We can offer convincing advantages in terms of service quality, time to market, seamless supply chain integration and novel manufacturing technologies,” Dr. Sousa added.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.
Cerbios’ is a global leading supplier of a portfolio of Generic APIs primarily used in Oncology, as well as in the treatment Respiratory and Dermatological disorders.
Exclusive CDMO services are offered for the development and manufacturing of high potency active ingredients (HPAIs) as well as for biological products including monoclonal antibodies, recombinant proteins, antibody drug conjugates (ADCs) and pharma probiotics.
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs, with paramount ability to supply all technical documentation and support necessary for successful registration. Cerbios’ commercial products are marketed worldwide, primarily in Europe, USA, Japan and India.
Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with AGC Biologics of Denmark and with Germany’s Oncotec.
PROVEO can offer an ADCs end-to-end service from substance development through manufacturing to fill & finish.
About World ADC Europe 2019
The World ADC Congress series is the industry’s longest standing and most comprehensive event devoted to Antibody Drug Conjugate technology and solutions, featuring events in Europe and North America that aim to generate new insights and connections to promote development of more clinically impactful ADCs.
The 9th ADC World Europe Congress 2019, will be a three-day event opening March 4 at the Hammersmith International Centre in West London.
The 2019 European congress will attract more than 300 professional delegates representing some 140 organizations to hear more than 50 expert speakers discuss a wide range of topics during three scientific tracks covering every element of ADCs from discovery, development, manufacturing and clinical applications.
The event is organized by Hanson Wade with more information at: http://worldadc-europe.com/